ASH Annual Meeting and Exposition

Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.

The combination of ibrutinib and venetoclax is well tolerated and eradicates minimal residual disease in the marrow after 12 months in 39% of patients with relapsed/refractory chronic lymphocytic leukemia.

The investigational agent zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, is highly active in patients with relapsed/refractory mantle cell lymphoma.

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.

Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.

Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.

Concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor T-cell therapy JCAR014 was well tolerated and led to an overall response rate of 83% in patients with relapsed or refractory chronic lymphocytic leukemia.

Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.

Treating younger patients with low-risk diffuse large B-cell lymphoma with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity without sacrificing efficacy, according to findings from the FLYER trial.

Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.

Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

Ibrutinib as monotherapy and combined with rituximab significantly improved progression-free survival compared with bendamustine plus rituximab as frontline therapy for older patients with chronic lymphocytic leukemia.

Ahead of the 2018 ASH Annual Meeting, multiple myeloma experts Sundar Jagannath, MBBS, selected the most pivotal abstracts in their field.

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

Frederick Locke, MD, Moffitt Cancer Center, discusses the results of the ZUMA-6 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab (Tecentriq) for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.

The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with BRAF-mutated and wild-type histiocytic disorders.

Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response versus hydroxyurea in patients with polycythemia vera.

About two-thirds of patients with hydroxyurea-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia had objective responses to pegylated interferon alfa-2a.

Two-thirds of older patients with acute myeloid leukemia achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine.

Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.

Almost half of patients with relapsed/refractory acute myeloid leukemia achieved complete response with the combination of selinexor (KPT-330) and AraC-containing chemotherapy.

Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.

Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.

The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.

Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).

The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.